The Pulse Newsletter Expert heart health, in plain English. Fortnightly, from our clinicians. Subscribe →
Section

Conditions

A heart diagnosis can feel overwhelming — but understanding what you have is the first step to feeling more in control. The Conditions section covers the most common heart and cardiovascular conditions in plain language, written by specialist cardiologists. From atrial fibrillation to heart failure, each guide explains what the condition means, how it’s treated, and what life looks like going forward.

Jump to a topic
All articles
Aortic Stenosis: When the Heart’s Gateway Narrows

Aortic Stenosis: When the Heart’s Gateway Narrows

The aortic valve opens and closes 100,000 times a day. When it begins to narrow, the heart pays the price. Here is how aortic stenosis develops, how it is diagnosed, and how modern treatment, from open surgery to TAVR, restores flow.

Patent Foramen Ovale (PFO): What the “Hole in the Heart” Finding Really Means

Patent Foramen Ovale (PFO): What the “Hole in the Heart” Finding Really Means

A patent foramen ovale, a small opening in the heart present in around one in four adults, can sound alarming when first mentioned. For most people it is entirely harmless and needs no treatment. Here is when it matters, and when it doesn't.

What is a Muscle Bridge?

What is a Muscle Bridge?

You have a muscle bridge. For most people that sentence means nothing needs doing. For a minority it explains real chest pain, and new research shows how the troublesome ones can be treated.

White Coat Hypertension: When Your BP Spikes at the Doctor’s

White Coat Hypertension: When Your BP Spikes at the Doctor’s

Your blood pressure reads high at every clinic visit but looks fine at home. White coat hypertension is one of medicine's most common and most misunderstood findings, and getting it right matters more than you might think.

Stroke and TIA Explained

Stroke and TIA Explained

Understanding stroke and TIA in plain language. This guide explains what each is, the investigations that follow, the medications used in prevention, and the lifestyle steps that support long-term brain health.

Hypertrophic Cardiomyopathy: What HCM Actually Means

Hypertrophic Cardiomyopathy: What HCM Actually Means

Most people with HCM live completely normal lives. Here is what the diagnosis means, what monitoring is needed, and why the outlook is better than most expect.

Stents or Bypass Surgery: How Your Heart Team Decides

Stents or Bypass Surgery: How Your Heart Team Decides

The decision between stents and bypass surgery is one of the most consequential in cardiology. Professor Patrick Serruys, who led the trial that created the evidence base for this decision, explains how it is made and what every patient should ask.

Single, Double, Triple, Quadruple Bypass: What Does the Number Mean?

Single, Double, Triple, Quadruple Bypass: What Does the Number Mean?

Hearing you need a triple bypass is alarming, but the number describes how many arteries were rerouted, not how dangerous the operation is. Understanding what it means can make one of the most daunting conversations in cardiac surgery far less frightening.

Does a Coffee a Day Keep AF at Bay?

Does a Coffee a Day Keep AF at Bay?

The landmark DECAF trial, published in JAMA, found that moderate coffee drinking may actually protect against AF recurrence — overturning decades of routine clinical advice.

Iron Deficiency and the Heart

Iron Deficiency and the Heart

Iron deficiency is one of the most common and most overlooked problems in cardiac patients — yet it is highly treatable.

SVT (Supraventricular Tachycardia) Explained: Causes and Treatment

SVT (Supraventricular Tachycardia) Explained: Causes and Treatment

SVT causes a sudden, rapid heartbeat, usually harmless but alarming. Knowing your triggers, diagnosis, and treatment options makes it manageable.

Rheumatic Heart Disease: A Preventable Condition Affecting Millions

Rheumatic Heart Disease: A Preventable Condition Affecting Millions

Rheumatic heart disease begins with an untreated strep throat and remains a leading cause of heart failure in young people across the developing world. Here is what you need to know.

How to Lower Blood Pressure Naturally

How to Lower Blood Pressure Naturally

High blood pressure often has no symptoms, but small changes to lifestyle, supplements, and medication can make a real difference.

Possible Old Heart Attack on ECG? What Q Waves Mean

Possible Old Heart Attack on ECG? What Q Waves Mean

n ECG report mentioning Q waves or a possible old heart attack is usually a normal variant. A cardiologist explains what the finding actually means.

A Living Legend of Interventional Cardiology: Professor Patrick Serruys

A Living Legend of Interventional Cardiology: Professor Patrick Serruys

One of the most influential cardiologists of the modern era, Professor Patrick Serruys helped shape the treatments, from drug-eluting stents to TAVI, that save lives today.

1234

When Blood Pressure Won’t Come Down: What Happens Next

Managing resistant hypertension — blood pressure monitoring and medication options explained by Prof. Peter Barlis

Blood pressure that stays high despite three or more medications has a name, and in most cases an explanation. What clinicians check first, why spironolactone is usually the fourth medicine added, and how narrow the role of renal denervation really is.

The Hair Loss Question

Hair loss and heart medicines
Key Points

  • Several medicines used in cardiology overlap with medicines used for hair, in both directions, which is why questions about hair loss often land with a cardiologist rather than a dermatologist.
  • Minoxidil, the treatment most people are asking about, began life as a blood pressure drug. The scalp solution rarely troubles the heart. The tablets retain a diluted version of the original effects.
  • Spironolactone, prescribed for heart failure and difficult blood pressure, also blocks the effects of male hormones. That is why it is used off-label for female pattern hair loss, and why some women notice a change in their hair while taking it.
  • The same hormonal effect makes spironolactone an unsuitable hair treatment for men, and this is the point most often missed.
  • Some hair loss is a signal rather than a cosmetic problem, including the shedding that commonly follows a heart attack, cardiac surgery, or any serious illness.

It is fair to wonder why a cardiologist is being asked about hair at all. The answer is that patients are increasingly being sent to ask.

Hair clinics and general practices now routinely tell people to check with their doctor about their heart before starting treatment, particularly minoxidil tablets. It arrives as a safety clearance rather than a cosmetic query, and it lands in a cardiology room because that is where it was sent.

There is a sound reason for that. Minoxidil was a blood pressure medicine long before it was a hair treatment, and it never entirely stopped being one. The overlap also runs the other way, because one of the medicines already sitting on many cardiac prescription lists is used by dermatologists for exactly this purpose.

Which is why the question, when it does come, is usually asked apologetically at the very end of the appointment, halfway out of the chair. It does not need to be. It is a question about medicines, and it belongs here.

Minoxidil, the One People Are Sent to Ask About

This is the treatment behind most of the clearance requests, and it has its own cardiovascular history.

It reached the market in the late 1970s as a treatment for severe hypertension. Patients taking it grew hair, and a topical formulation followed in the 1980s. Brand names differ from country to country, so the generic name minoxidil remains the reliable identifier on any packet, and available strengths vary by market.

Minoxidil opens potassium channels in the smooth muscle of small arteries. Those vessels relax and blood pressure falls. The body compensates by retaining salt and water and by raising the heart rate, which is why minoxidil tablets at blood pressure doses were almost always paired with a diuretic and a beta-blocker.

The scalp solution

Applied to intact scalp, only a small proportion of a topical dose reaches the bloodstream, far too little in most people to move blood pressure or heart rate measurably. Palpitations, lightheadedness, and mild ankle swelling have been described, but they are uncommon and tend to follow generous application, use over inflamed or broken skin, or unusual sensitivity to vasodilators.

Low-dose tablets

The bigger change over the past few years has been dermatologists prescribing minoxidil tablets at low doses, a small fraction of the intensity once used for hypertension. The largest published safety experience, a review of 1,404 patients across 10 centres in six countries, found side effects that were mostly mild. Hair growth in unwanted places was by far the most common, affecting about 15% of patients. Lightheadedness, fluid retention, and a faster heart rate each appeared in under 2%, and fewer than one in 50 people stopped treatment because of a side effect.

Hair in other places

The most frequently reported effect. Fine hair on the face, forearms, or upper back. It is not dangerous and it settles once the tablet is stopped.

Fluid retention

Salt and water retention is built into how the drug works. It shows up as puffy ankles or a small rise in weight, and it matters far more in a heart that is already struggling.

Heart rate and blood pressure

A slightly faster resting pulse and a small fall in blood pressure are both expected. People already taking several blood pressure medicines feel this more.

Where the frightening warnings came from

Anyone reading the product information for minoxidil tablets will find warnings about fluid collecting around the heart and about angina becoming worse. These are real, and they are also a product of their era, written from experience with high-dose treatment in patients who had severe hypertension, often alongside significant kidney disease, before modern blood pressure regimens existed. Pericardial effusion, meaning fluid in the sac surrounding the heart, was described in that setting and is identified on an echocardiogram.

At the doses used for hair, events of that severity appear to be rare rather than routine. Rare is not the same as impossible. The fair summary is that low-dose oral minoxidil has a reassuring short-term record in relatively healthy people, and a much thinner evidence base in those with established heart disease, because they are the patients least likely to have been studied.

Minoxidil at blood pressure doses also carries a rebound risk. Stopping abruptly removes the vasodilation while the compensating fluid retention and faster heart rate are still present, and blood pressure can overshoot. That is why the dose is usually stepped down rather than halted outright. Whether, when, and how to stop is a decision for the prescribing doctor, who may reasonably choose to stop immediately if a serious effect appears.

Feature Topical Low-Dose Oral
Brand names (vary by country) Several major brands Usually generic tablets
Reaches the bloodstream A small percentage Effectively all of it
Availability Over the counter in most markets Prescription, and off-label
Common nuisance effects Scalp irritation and itching Unwanted hair, puffy ankles
Cardiovascular relevance Low for most people Modest, worth reviewing
Dose strengths Vary by market Far below blood pressure doses

The situations that usually prompt a fuller review before oral minoxidil is considered are heart failure, known pericardial disease, significant valve disease, pulmonary hypertension, recent unstable angina, reduced kidney function, and a blood pressure regimen that is already crowded. In that last group, home blood pressure readings become genuinely useful information.

Spironolactone, the Medicine Already on the List

Spironolactone is a familiar name in cardiology. It is a mainstay of treatment in heart failure with reduced ejection fraction and one of the more useful options when blood pressure refuses to come down on three other agents.

Less widely known is that it does two things at once. Alongside its effect on salt and water handling, it blocks androgen receptors and reduces the production of male hormones. Androgens are central to pattern hair loss, which is why dermatologists reach for spironolactone in female pattern hair loss, acne, and polycystic ovary syndrome.

So a woman taking spironolactone for her heart who reports that her hair seems less thin is not imagining a mechanism. There is a plausible one, and it is the same mechanism a dermatologist would have been aiming for deliberately.

What the evidence actually supports

The evidence here is honest but modest. Most of it comes from observational series and clinical consensus rather than large randomised trials, and it points toward a partial effect that develops slowly, over many months, in some women rather than all of them. That is worth taking seriously. It is not a promise.

The doses are not the same

There is a further complication. The doses commonly used in dermatology sit above those used in heart failure, where treatment is deliberately conservative to protect kidney function and potassium levels.

Someone taking spironolactone for a cardiac reason is therefore receiving an amount that may or may not be doing much for their hair. A welcome side effect is a reasonable thing to enjoy. It is not a reason to start the drug, or to want more of it.

Why this is a different conversation for men

This is the point that gets lost fastest once the phrase “spironolactone helps hair” is in circulation.

Blocking androgens has consequences that men notice. Breast tenderness and breast tissue enlargement, known as gynaecomastia, are well recognised and become more likely at higher doses. Reduced libido is also reported. These are the reasons spironolactone is not used as a hair loss treatment in men.

Men already prescribed it for heart failure are a separate matter. There the cardiac benefit is substantial and well established, and the hormonal effects are managed as a known trade-off rather than pursued.

Potassium, and the combinations that matter

Spironolactone causes the body to retain potassium. That is intrinsic to how it works, and in most people it is handled without difficulty.

It becomes more delicate in combination. ACE inhibitors, angiotensin receptor blockers, sacubitril with valsartan, potassium supplements, and some anti-inflammatory painkillers all push potassium in the same direction, and reduced kidney function narrows the margin further. Blood tests before starting and at intervals afterwards are the standard way this is monitored, and they are the reason spironolactone is prescribed rather than borrowed from a relative’s cabinet.

Spironolactone is also avoided in pregnancy, because an antiandrogen affects a developing baby.

Finasteride and dutasteride, the other treatments raised most often, work on hormone conversion rather than on blood vessels. No consistent cardiovascular signal has emerged from the trial data, and the discussions around them concern sexual side effects and mood rather than the heart.

The GLP-1 Question

A study published in The BMJ in July 2026 looked at this directly. Researchers followed adults with type 2 diabetes starting a GLP-1 receptor agonist and compared them with people starting two other classes of glucose-lowering medicine. Newly recorded hair loss was more common in the GLP-1 group, by roughly 40% to 70% depending on the comparison.

Three things temper that. The absolute numbers were small, at around seven cases per 1,000 people a year against four to five in the comparison groups. The excess was concentrated in non-scarring hair loss, the diffuse and usually reversible kind linked to rapid weight change. And a study built on diagnoses recorded during routine care cannot fully separate an effect of the drug from an effect of losing weight quickly.

The study was done in one large health system and in people with diabetes, so it does not settle the question for everyone taking these medicines. It matters here because semaglutide and related medicines are now prescribed for cardiovascular reasons and not only metabolic ones. An effect on hair that is usually reversible sits on a very different scale from a reduction in heart attacks and strokes.

When Hair Loss Is a Signal Rather Than a Complaint

Not all hair loss is pattern baldness, and some of it points back toward the heart. A heart attack, cardiac surgery, or any major physiological stress can push a large proportion of hair follicles into their resting phase at once. The shedding arrives two to four months later, by which time most people have stopped connecting the two events.

Growing

Most follicles.
Lasts years.

Resting

A small minority.
Root pulls upward.

Shedding

Follicle empties,
then restarts.

Resting to shedding takes two to four months

A shock to the body pushes many follicles into the resting phase together, so they shed as a group months after the event.

Iron deficiency and thyroid disease belong in the same category. Both cause hair loss, both are common in people with heart disease, and both are treatable once found.

Questions Patients Ask Me Most

These are the ones that come up again and again in clinic, answered as plainly as I can. As always, this is general information, and any decision about your own medicines belongs in a conversation with your doctor.

Can I use the scalp solution if I have a heart condition?

Mostly reassuring

For most people with stable heart disease, topical minoxidil is not the thing a cardiologist is concerned about. Very little of it reaches the bloodstream through intact scalp. It is still worth mentioning at your next appointment, particularly if you have heart failure or your blood pressure is being actively adjusted.

I am already on spironolactone. Will it help my hair?

Worth discussing

It might, if you are a woman with pattern hair loss, and some women do notice a change. The effect is partial, gradual, and not universal, and the doses used in dermatology usually sit above cardiac doses. It is a welcome bonus if it happens, rather than something to count on or to ask for more of.

If it works for women, can a man take it for hair?

Worth discussing

Spironolactone is not used as a hair treatment in men. The same hormone blocking that helps some women causes breast tenderness and breast tissue enlargement in men, and reduced libido is also reported. Men taking spironolactone for heart failure are in a different situation, where the cardiac benefit is the point.

My hair started falling out after my heart attack. Is it the medication?

Mostly reassuring

Usually not. Shedding that begins two to four months after a heart attack, cardiac surgery, or a serious illness is far more often telogen effluvium, the body’s delayed response to the stress itself. It is diffuse rather than patchy and it recovers on its own in most cases. Iron levels and thyroid function are worth checking.

Should I stop my weight loss injection if my hair thins?

Worth discussing

That is a conversation to have rather than a decision to make alone. The hair loss described with these medicines is the reversible kind and the absolute risk is small, while the cardiovascular benefit for people who qualify is substantial. Stopping a medicine prescribed to reduce heart attacks and strokes is not a step to take over hair without advice.

Is there anything worth checking before I try something?

Mostly reassuring

Iron studies and thyroid function are the two most commonly useful tests, because both cause hair loss, both are common in people with heart disease, and both are treatable. Kidney function and potassium matter if spironolactone is being considered. These are simple blood tests rather than anything elaborate.

Heart Matters Resource

When in Doubt, Get Checked Out

New swelling, unexplained weight gain, or a racing pulse after starting any new medicine are worth reviewing properly rather than waiting to see whether they settle.

Read: When in Doubt, Get Checked Out →

Conclusion

Hair and the heart share more pharmacology than either specialty tends to advertise. One widely used cardiac medicine has a genuine effect on hair in women and a set of reasons not to use it that way in men. The best known hair treatment was a blood pressure drug first and never entirely stopped being one.

So when a hair clinic or a GP sends someone to have their heart checked before starting treatment, that is a sensible instruction rather than a formality. For most people the answer will be straightforward. Knowing which people it is not straightforward for is the reason the question is worth asking at all.

Related Reading

Aortic Dissection: The Chest Pain That Cannot Wait

aortic dissection
Key Points

  • An aortic dissection is a tear in the wall of the aorta, the body’s main artery. It is a medical emergency, and every minute counts.
  • The warning sign is sudden, severe chest or back pain, often described as ripping or tearing, and often the worst pain a person has ever felt. It arrives at full intensity within seconds rather than building gradually.
  • Long term high blood pressure is the single biggest risk factor. Most people who have a dissection have had raised blood pressure for years.
  • Inherited conditions such as Marfan syndrome, and a family history of aortic aneurysm or unexplained sudden death, substantially increase risk and are a reason to ask about screening.
  • Dissection is easily mistaken for other conditions, and a normal ECG or normal blood test does not rule it out. If the pain fits the pattern, call 000.

Most cardiac emergencies announce themselves gradually. A heaviness in the chest that builds over minutes. A tightness that comes on with exertion and eases with rest. An aortic dissection does not behave this way. It arrives at full force, without warning, in people who felt perfectly well moments earlier.

It is the emergency that gives no notice. A person is well in the morning, well over lunch, and in cardiac arrest by the evening. That pattern is not a rare exception to how dissection behaves. It is characteristic of it.

Understanding what an aortic dissection is, who is at risk, and above all what it feels like, is the difference between a call to emergency services and a fatal delay.

What Is an Aortic Dissection?

The aorta is the largest blood vessel in the body. It leaves the heart, arches over the top of it, and travels down through the chest and abdomen, carrying every drop of blood the heart pumps out to the rest of the body. It is roughly the width of a garden hose, and it withstands enormous pressure with every heartbeat.

The wall of the aorta is made of three layers, bonded together. A dissection begins when the innermost layer develops a tear. Blood, travelling at high pressure, is forced into that tear and begins to push the layers apart, carving a false channel along the length of the vessel.

Once that channel opens, several things can go badly wrong at once. The false channel can compress the true one, starving organs of blood. It can extend into the branches that supply the brain, kidneys, or the heart muscle itself. It can rupture entirely. And if the tear is close to the heart, blood can leak into the sac that surrounds it, squeezing the heart until it can no longer pump.

The Two Types, and Why the Difference Matters

Doctors classify dissections by where the tear sits. This is not academic. The two types are treated in fundamentally different ways.

Type A dissections involve the ascending aorta, the section closest to the heart. These are surgical emergencies. The tear can extend backwards into the sac around the heart or shear off the arteries feeding the heart muscle, and either can cause sudden cardiac arrest. Type A dissections are taken directly to theatre.

Type B dissections are confined to the descending aorta, further down the chest. These are often managed initially with aggressive blood pressure control in intensive care, with a stent placed inside the vessel in selected cases. Surgery is not always the first step.

Type A

The tear involves the section of aorta nearest the heart. This is the more dangerous form and is treated as an immediate surgical emergency.

Type B

The tear is confined to the descending aorta, further from the heart. Often managed first with intensive blood pressure control, and sometimes a stent.

Why Time Matters

For an untreated Type A dissection, the risk of death rises with every hour that passes after the tear. This is why it is never something to wait out.

What It Actually Feels Like

This is the section worth remembering, because recognising the pain is what gets people to hospital in time.

The classic symptom is sudden, severe pain in the chest or back. Patients describe it as ripping, tearing, or being stabbed. It is frequently described as the worst pain of their life. Two features set it apart from most other chest pain.

First, the onset. It does not build. It is maximal within seconds. People can often tell you exactly what they were doing at the moment it began.

Second, it can move. As the tear extends along the vessel, the pain can travel, migrating from the front of the chest through to between the shoulder blades, or down into the abdomen.

Dissection can also present in ways that look like something else entirely. Stroke-like symptoms if the tear reaches the arteries to the brain. Abdominal pain. Fainting. A leg that suddenly turns cold and pale. In the most severe cases, the first sign is collapse. This was the pattern in the widely reported death of United States Senator Lindsey Graham in July 2026, whose office cited preliminary findings of an aortic dissection due to arteriosclerotic cardiovascular disease. He was 71, had recently returned from an overseas trip, and had shown no sign of being unwell.

Chest pain that arrives at full intensity in an instant, and is described as tearing or ripping, is not a wait and see symptom. It is a call an ambulance symptom.

Why Blood Pressure Sits at the Centre of This

The most important thing to understand about dissection is that in the majority of cases, it is the endpoint of a process that has been building quietly for years.

Every heartbeat sends a pulse of pressure through the aortic wall. Over decades, persistently high blood pressure stresses that wall, stiffening it and degrading the elastic tissue that holds the layers together. Add the plaque and inflammation of atherosclerosis, the same disease process that drives most heart attacks and strokes, and the wall becomes progressively less able to tolerate the pressure it is subjected to.

Chronic hypertension is the single biggest modifiable risk factor for aortic dissection, and it is present in the large majority of cases. This is the uncomfortable but hopeful part of the story. A condition that kills within minutes is driven, more than anything else, by a number that can be measured at home in 60 seconds and treated effectively.

The other well-recognised contributors are:

  • Age and sex. Dissection most commonly affects men in their 60s and 70s, though it can occur far younger, particularly where there is an inherited cause.
  • Smoking. Tobacco accelerates the arterial damage that weakens the aortic wall.
  • An existing aortic aneurysm. A vessel that has already enlarged is a vessel more likely to tear.
  • Stimulant drug use. Cocaine and amphetamines cause abrupt, extreme blood pressure surges.
  • Pregnancy. Uncommon, but a recognised period of increased risk in women with underlying aortic disease.

The Genetic Side, and When Family History Matters

Not every dissection is a story about decades of blood pressure. A meaningful minority occur in younger people whose aortas were structurally vulnerable from birth.

Inherited connective tissue conditions

Marfan syndrome is the best known. It affects the connective tissue that gives the aortic wall its strength, and people with Marfan syndrome can experience dissection in their 30s or 40s. Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome carry similar risk. These conditions often, though not always, come with recognisable physical features such as tall stature, long limbs and fingers, and problems with the lens of the eye.

Bicuspid aortic valve

Some people are born with an aortic valve that has two leaflets instead of the usual three. This is one of the most common congenital heart differences, and it is associated with weakness in the wall of the ascending aorta, independent of any valve problem. It is also relevant to aortic stenosis later in life.

Familial aortic disease with no syndrome attached

This is the group most often missed. Some families carry a tendency to aortic aneurysm and dissection without any of the classical syndromes and without any outward clues. The only signal is the family history itself.

If a parent, sibling, or child has had an aortic aneurysm, an aortic dissection, or an unexplained sudden death, that is worth raising with your doctor. Imaging can measure the size of the aorta long before it is in danger, and an aorta that is enlarging can be monitored, treated with blood pressure medication, and repaired electively. Elective repair is a very different proposition to emergency surgery on a tearing vessel.

Why It Is So Easily Missed

Aortic dissection is one of medicine’s great imitators, and this is worth understanding because it affects what you should do.

The standard tests used to assess chest pain, an ECG and a blood test for cardiac enzymes, can be entirely normal while the aorta is tearing. A chest X-ray is often unremarkable. The diagnosis usually rests on a CT scan of the aorta, and that scan only gets ordered if someone thinks to order it.

This has two practical implications. If you experience sudden tearing chest or back pain, say so in exactly those words to the paramedics and to the doctor in the emergency department. The description matters. And if you have a family history of aortic disease, say that too, unprompted. It changes how the pain in front of the doctor is interpreted.

It is entirely reasonable, in that situation, to ask directly whether an aortic dissection has been considered. Good clinicians will not be offended by the question.

What You Can Actually Do

The measures that protect the aorta are not exotic. They are the same measures that protect the rest of the cardiovascular system, applied consistently over years.

Know your blood pressure and treat it. If you have been prescribed medication for it, take it. This matters more than any other single action, and there is a great deal you can do alongside medication to help bring the numbers down.

Do not smoke. Treat raised cholesterol. Stay physically active. Understand your overall cardiovascular risk profile rather than any single number in isolation.

And know the alarm symptom. Sudden, severe, tearing chest or back pain, arriving at full intensity, in a person who was well moments before, is an emergency until proven otherwise. In Australia, call 000. Do not drive yourself. Do not wait to see whether it settles.

Conclusion

An aortic dissection is one of the few conditions in cardiovascular medicine where outcome is measured in minutes rather than hours or days. It is also, for most people, the final chapter of a much longer and much quieter story, one written by years of untreated blood pressure and arterial damage. That is the part that is within reach.

Take the blood pressure reading. Ask about the family history. And if the pain ever comes, sudden and tearing and unlike anything before it, do not talk yourself out of the phone call.

Related Reading

Demystifying Heart Failure: HFrEF, HFpEF and HFimpEF Explained

heartmatters.com 2026 04 01T171429.222
Key Points

  • Heart failure does not mean the heart has stopped or is about to. It means the heart is not pumping or filling as efficiently as it should, and in many cases this can be treated and even improved.
  • The confusing letters (HFrEF, HFpEF, and the newer HFimpEF) all describe one thing: the ejection fraction, or how much blood the main pumping chamber squeezes out with each beat.
  • Cardiologists separate these types because the underlying problem and the best treatment differ. The same label points the whole team toward the right medicines.
  • HFimpEF (improved ejection fraction) is the hopeful category. It describes people whose heart function has recovered, and the key lesson is that the medicines usually need to continue.
  • A new international consensus, the Second Universal Definition of Heart Failure published in June 2026, reframes heart failure as a condition that can change over time, with more focus on catching it early.

You have been told you have heart failure, and within the same conversation you have heard HFrEF, HFpEF, and perhaps HFimpEF. It sounds like alphabet soup, and it arrives at exactly the moment you are least equipped to decode it. The good news is that these terms are far less frightening once you understand what they are actually measuring, and why your cardiologist cares about the difference.

This article breaks the language down into plain English: what heart failure really means, what those letters stand for, why the distinction matters for your treatment, and what a major new international definition, published in June 2026, changes for patients.

Start With What Heart Failure Actually Means

The name is one of the cruellest in medicine. “Failure” suggests something has stopped, or is about to. That is not what it means. Heart failure is a clinical syndrome in which the heart cannot pump or fill with blood as efficiently as the body needs, usually producing symptoms such as breathlessness, fatigue, and swelling in the legs and ankles.

Crucially, it is not a single disease and it is not a death sentence. It is a description of how the heart is performing, and modern treatment can stabilise it, ease symptoms, and in a meaningful number of people improve the heart’s function substantially. To understand the categories, you first need to understand one number.

The Number Behind the Letters: Ejection Fraction

Every time the heart’s main pumping chamber, the left ventricle, contracts, it squeezes a percentage of the blood inside it out to the body. That percentage is the ejection fraction, usually shortened to EF. It is measured most often on an echocardiogram, the heart ultrasound.

A normal left ventricle does not empty completely. A healthy EF sits somewhere around 55% to 70%. So an EF of 60% is normal, not a sign that 40% is being left behind in a worrying way. This is the single most misread number in a cardiology report, so it is worth pausing on: a lower EF means the pump is weaker, but the EF is only one part of the picture, and it is not the whole story of how you will feel or fare.

The Three Main Types, Explained

Heart failure is grouped by ejection fraction because that number, more than almost anything else, tells the cardiologist what kind of problem they are dealing with and which treatments are likely to help. Here are the categories you are most likely to hear.

HFrEF: heart failure with reduced ejection fraction

This is the “weak pump” type. The EF is reduced, conventionally 40% or below, meaning the left ventricle is not contracting forcefully enough. The heart muscle has usually been damaged or weakened, and the squeeze is impaired. HFrEF is the type with the largest body of evidence behind its treatment, and, importantly, the type where the right combination of medicines can make the biggest difference.

HFpEF: heart failure with preserved ejection fraction

Here the EF is preserved, conventionally 50% or above, so the pump looks normal on paper. The problem is not the squeeze but the relaxation and filling. A stiff left ventricle cannot relax properly between beats, so it fills poorly and pressure backs up, producing the same symptoms of breathlessness and swelling. HFpEF is more common in older adults, in women, and in people with long-standing high blood pressure, diabetes, or obesity. For years it was the harder type to treat, though that has changed recently.

HFimpEF: heart failure with improved ejection fraction

This is the newest and most hopeful category. It describes someone who started with a reduced EF (40% or below) and, with treatment, has seen it recover to above 40%. Their heart has improved. The vital message attached to this label, and the reason cardiologists coined it rather than simply calling the person “better,” is that the improvement is usually because of the medicines, not instead of them. Stopping treatment because the numbers look good is one of the most common ways people relapse.

You may also hear HFmrEF, heart failure with mildly reduced ejection fraction, describing the middle band where EF sits between 41% and 49%. Think of it as the territory between the reduced and preserved categories, treated with a foot in both camps.

HFrEF: reduced

The pump is weak. Ejection fraction 40% or below. The muscle is not squeezing hard enough. Strong evidence exists for treatment that helps the heart recover.

HFpEF: preserved

The pump looks normal (EF 50% or above) but the ventricle is stiff and fills poorly. More common with age, in women, and with high blood pressure or diabetes.

HFimpEF: improved

Started reduced, now recovered above 40%. The good-news category, with one rule: the medicines that produced the recovery usually need to continue.

Why Cardiologists Bother Splitting Hairs

It is a fair question. If the symptoms are similar, why label the types at all? The answer is that the underlying mechanics are genuinely different, and so is the treatment that works. A medicine proven to save lives in a weak, reduced-EF heart may do little for a stiff, preserved-EF heart, and vice versa. The category is not bureaucratic tidiness. It is the shorthand that points your whole care team toward the treatments most likely to help you, and away from ones that will not.

Getting the category right also shapes what your cardiologist watches over time, from your BNP blood test to repeat scans that track whether your EF is holding steady, worsening, or improving.

The table below sets the three types side by side. It is a map, not a diagnosis, and your own cardiologist remains the person who reads it onto your particular heart.

Feature HFrEF (reduced) HFpEF (preserved) HFimpEF (improved)
Ejection fraction 40% or below 50% or above Was 40% or below, now above 40%
Core problem A weak squeeze A stiff chamber that fills poorly A previously weak heart that has recovered
More common in People with prior muscle damage or a weakened heart Older adults, women, and people with high blood pressure or diabetes People treated early and effectively for HFrEF
Treatment focus The four pillars of medicine, built up together Treating the drivers, plus SGLT2 inhibitors Continuing the medicines that produced the recovery
Outlook message Strong evidence that treatment helps Improving fast as new evidence arrives The hopeful category, if treatment continues

The label is not there to frighten you. It is there to make sure the right medicine reaches the right heart.

What Causes Each Type

The causes overlap, but they cluster differently across the categories, and identifying the cause is often as important as measuring the EF.

Reduced-EF heart failure most often follows damage to the heart muscle: a previous heart attack that has left a weakened area, longstanding uncontrolled blood pressure, disease of the heart muscle itself (the cardiomyopathies), heart rhythm problems such as atrial fibrillation, valve disease, or, in some people, alcohol and certain toxins.

Preserved-EF heart failure tends to grow out of years of a heart working against stiffening and pressure: chronic high blood pressure, diabetes, obesity, obstructive sleep apnoea, and ageing itself. Less commonly, an infiltrative condition such as cardiac amyloidosis stiffens the muscle, which matters because some of these causes now have specific treatments.

Improved-EF heart failure, by definition, starts as the reduced type and gets better, usually because the cause was treatable and the treatment worked. That is precisely why the medicines are rarely a temporary measure.

How Each Type Is Treated

This is where the categories earn their keep. The following is a general map, not a prescription. The right combination, and every dose, is individual, and only your own cardiologist can advise what is right for you.

For reduced-EF heart failure, the modern approach uses four classes of medicine together, often called the four pillars or quadruple therapy. In broad terms these are a medicine that relaxes and protects the blood vessels and heart (an ACE inhibitor, an ARB, or the combination agent Entresto), a beta-blocker, a mineralocorticoid receptor antagonist such as spironolactone, and an SGLT2 inhibitor. Used together and built up carefully, this combination has transformed outcomes over the past decade.

For preserved-EF heart failure, the picture has brightened considerably. SGLT2 inhibitors now have good evidence here too, which was not the case a few years ago. Beyond that, the priority is treating the drivers: controlling blood pressure and diabetes, managing weight, addressing sleep apnoea, and using diuretics to clear the fluid that causes congestion and breathlessness. Treating the specific cause, where there is one, matters more in this group than in any other.

For improved-EF heart failure, the treatment is, in most cases, to keep going. Trials have shown that stopping the medicines once the heart has recovered often allows the weakness to return. The recovery is best understood as the treatment succeeding, not as the illness disappearing, and the safest path is to maintain the therapy under your cardiologist’s guidance. Never stop a heart failure medicine without speaking to them first.

What the New 2026 Definition Changes

In June 2026, the world’s leading cardiovascular bodies, including the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the World Heart Federation, published the Second Universal Definition of Heart Failure, simultaneously in the journals JACC, Circulation, the European Heart Journal, and Global Heart. The American Heart Association has also released a plain-language summary for patients. It updates the first such definition from 2021, and although the document is written for clinicians, several of its changes matter to patients.

64 million
adults worldwide are estimated to live with heart failure, a number driven up by ageing populations and rising rates of high blood pressure, diabetes, and obesity.
American Heart Association, June 2026

First, it moves away from rigid cut-off numbers for ejection fraction and acknowledges that a normal EF differs by sex, age, and ethnicity, while keeping the familiar reduced, preserved, and improved categories as practical guides. Second, it puts far greater emphasis on catching heart failure early, before symptoms appear, so that prevention and treatment can start sooner. Third, and perhaps most reassuringly, it formally describes heart failure as a dynamic condition that can improve, go into remission, or progress, rather than a fixed, one-way diagnosis. The document is intended to be the foundation for the next major heart failure guideline, expected in 2027.

For a patient, the takeaway is encouraging: the field increasingly sees heart failure not as a static verdict but as a condition to be caught early, categorised accurately, and, in many people, improved.

Questions Worth Asking at Your Next Appointment

  • Which type of heart failure do I have, and what does that mean for my treatment?
  • What is my ejection fraction, and has it changed since my last echocardiogram?
  • Am I on the right combination of medicines for my specific type?
  • Are there conditions contributing to my heart failure, such as blood pressure, diabetes, or weight, that we should be managing more closely?
  • What symptoms should prompt me to contact the team between appointments?

Heart Matters Resource

When in Doubt, Get Checked Out

New breathlessness, unusual tiredness, or swelling in the legs are worth having assessed early. Heart failure is far more treatable when it is picked up sooner rather than later.

Read: When in Doubt, Get Checked Out →

Conclusion

The terminology around heart failure sounds far more alarming than the reality for most people. HFrEF, HFpEF, and HFimpEF are simply three ways of describing how well the heart’s main chamber is pumping and filling, and each points toward a different and increasingly effective set of treatments. The letters are a tool for getting you the right care, not a measure of how worried you should be.

If you have been given one of these labels, the most useful thing you can do is understand which type you have, take the medicines as prescribed even if you feel well, and keep the conversation with your cardiologist going. Heart failure is more treatable today than at any point in medical history, and, as the newest category reminds us, it can genuinely improve.

Related Reading

AI in Cardiology: What It Means for Your Heart, and What It Cannot Do

AI in cardiology, heart
Key Points

  • Artificial intelligence is already being used in cardiology, quietly and carefully, in ways that are genuinely improving patient care.
  • AI does not replace your cardiologist. It gives them better tools, more time, and sharper information to make decisions with you.
  • From reading ECGs to analysing intracoronary imaging, planning complex procedures, and assessing heart valves, AI is being applied across almost every area of heart medicine.
  • Neural networks are already shortening the time taken to analyse complex imaging, making procedures faster and more accurate.
  • The goal is the same as it has always been: getting the right treatment to the right patient.

If you have heard the term artificial intelligence, or AI, mentioned in the context of medicine, and been unsure whether to find it exciting or unsettling, you are not alone. The term carries a lot of weight in public conversation, and not always in reassuring directions.

So let us be clear about something from the outset. The AI being developed and applied in cardiology is not about replacing doctors, or making decisions by algorithm, or removing the human relationship at the heart of medicine.

It is about giving cardiologists better tools. Tools that can process more information more quickly, spot patterns that are difficult for the human eye to detect, and help ensure that every patient benefits from the full weight of accumulated medical knowledge, not just the experience of the individual clinician in front of them.

As one of the leading figures applying AI to cardiovascular research and daily clinical practice, my view is clear. AI is here to help improve workflow, and that efficiency creates more face-to-face time with patients. Not less.

What Do We Actually Mean by AI in Cardiology?

AI is a broad term that encompasses several different technologies. In cardiology, the most relevant are machine learning, where a computer learns to recognise patterns by analysing large amounts of data, and deep learning, a more sophisticated version that can analyse complex images such as heart scans with remarkable accuracy.

Neural networks, modelled loosely on the structure of the human brain, sit at the heart of many of these systems. They are capable of identifying patterns in imaging data at a speed and consistency that no human analyst could match.

These are not futuristic concepts. They are already in use in hospitals and catheterisation laboratories around the world, often in ways that patients would not notice. They run quietly in the background, helping clinicians interpret information faster and more accurately than would otherwise be possible.

Speaking at the 2026 European Association of Percutaneous Cardiovascular Interventions Summit in Munich, I described AI as transforming cardiology at a pace that is genuinely unprecedented, having been at the forefront of applying machine learning to some of the largest datasets in coronary disease research, including the SYNTAX trial, which followed 1,800 patients for 10 years.

But alongside that enthusiasm, I was equally clear about the caution required. To trust an AI estimation more than clinical expertise, we have to be certain it has been proven in outcomes studies. Progress, but never at the expense of safety. That balance, genuine excitement tempered by rigorous caution, is precisely what patients should expect from the doctors leading this field.

Where Is AI Already Making a Difference?

The clearest way to understand where AI sits in modern cardiology is to follow the journey a patient takes, from the moment a problem is first suspected through to the treatment decision and beyond. At every stage of that journey, AI is already at work.

How AI Works in Cardiology
From data to clinical decision
1

Data Input

ECG readings, CT scans, echo images, blood tests, and your medical history are gathered, the raw information about your heart.

2

Neural Network

Trained on millions of examples, the AI identifies patterns in that information that are invisible to the human eye.

3

Analysis

Risk scores, measurements, plaque characterisation, and predictions are produced in seconds rather than hours.

4

Your Cardiologist

Reviews the AI output alongside clinical judgement and makes the final decision with you.

AI informs. Your cardiologist decides.

Stage 1: before you ever reach a specialist

AI is already working before most patients know they have a problem. Tools trained on millions of ECG recordings can now detect patterns associated with heart attacks, irregular rhythms, and structural heart disease with accuracy that matches experienced clinicians. Some of these tools are built into smartwatches and portable devices, bringing ECG analysis into patients’ own homes.

In resource-limited parts of the world, AI-powered digital stethoscopes and portable devices are allowing patients in communities without specialist cardiologists to be assessed and triaged to a standard that previously required a fully equipped hospital. A patient who would once have waited months to see a specialist, or never seen one at all, can now have their heart rhythm analysed, their valve function assessed, and their cardiovascular risk stratified using tools that fit in a small case.

This matters more than almost any other application of AI in medicine. The burden of cardiovascular disease falls most heavily on low- and middle-income countries, precisely the places with the fewest cardiologists, the least access to imaging equipment, and the longest distances between patients and the hospitals that could help them.

AI does not fix those structural problems. But it does mean that a community health worker in a rural clinic, equipped with a smartphone and a portable ECG device, can now make a triage decision that would previously have required a trained cardiologist. The technology does not replace the specialist. It extends their reach to places they cannot physically be.

Stage 2: investigating your heart

Once a problem is suspected, you will be referred for tests. This is where AI is already embedded most deeply in clinical practice.

Computed tomography coronary angiography, or CTCA, uses X-ray technology to produce detailed images of the coronary arteries. AI and machine learning are now being used to interrogate these datasets far beyond what conventional analysis could achieve. The presence, extent, and characteristics of plaque can be assessed with a granularity that helps your clinical team make better-informed decisions before you ever reach the procedure room.

The echocardiogram, the ultrasound of the heart, is one of the most widely used diagnostic tools in cardiology. Machine learning algorithms can now assist in assessing heart valve function with impressive accuracy. What is particularly striking is that the benefit is greatest for less experienced operators. A sonographer early in their training, using an AI-assisted system, can achieve diagnostic accuracy that would previously have required years of experience.

In some centres, robotic echocardiography systems guided entirely by AI are now acquiring images without a sonographer needing to hold the probe at all, opening up access to high-quality cardiac imaging in areas where specialist staff are scarce.

Stage 3: planning your procedure

When treatment is needed, AI is transforming how your clinical team prepares. Computational fluid dynamics, or CFD, combines your imaging data with mathematical modelling of blood flow to simulate how blood actually moves through your coronary arteries, and how different treatment strategies will change that flow. The procedure can effectively be planned and rehearsed virtually before it is performed.

This goes further still with what might be called a digital twin: a precise virtual replica of your specific heart and coronary anatomy, built from your own imaging data. Different treatment approaches can be tested on this model, complications anticipated, and the optimal strategy identified, all before you enter the operating theatre.

I am actively collaborating with Professor Peter Barlis and his team, and at the Peter Barlis Laboratory we have been using AI to simulate blood flow at bifurcation points, the branching junctions where blockages are most technically challenging to treat, with the goal of improving precision and safety for each individual patient.

“Where is AI most useful in cardiology? Preplanning. Planning is everything.”

Prof. Patrick Serruys, Interventional Cardiologist

Stage 4: in the procedure room

Once you are in the catheterisation laboratory, AI is present in real time. Intracoronary imaging techniques such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS) look inside the coronary arteries during procedures and generate large amounts of imaging data. Neural networks can now analyse this data at a speed that would have been unimaginable a decade ago. They characterise plaque, identify high-risk features, and predict the result of a stenting procedure, all in the time it takes to complete the procedure itself.

AI is also reading the angiogram in real time as your cardiologist works, automatically measuring the degree of narrowing, the length of the blockage, and the appropriate stent size. A randomised clinical trial has shown that AI-guided angiography analysis produces results comparable to the most detailed imaging techniques available. This is AI genuinely in the room, providing an objective second opinion at the most critical moment of the procedure.

Stage 5: choosing your treatment

Perhaps the most directly relevant application of AI for patients is in the decision between stenting and bypass surgery. Rather than a broad population-based recommendation, machine learning models applied to the SYNTAX trial dataset were able to distinguish meaningfully between patients who looked similar on the surface but whose predicted outcomes differed significantly depending on which treatment they received.

Research Spotlight

The blood tests that turned out to matter more than anyone realised

When the SYNTAX trial dataset was analysed using machine learning, two findings stood out. C-reactive protein, a blood test that measures inflammation, and haemoglobin levels, which reflect anaemia, both emerged as powerful predictors of long-term outcomes after heart treatment. Neither had featured prominently in conventional cardiology risk scoring.

A further surprise was gamma-glutamyl transferase, a liver enzyme routinely measured in blood tests but not traditionally associated with heart outcomes. The machine learning model identified it as a significant predictor of 10-year outcomes. I was initially sceptical, but the finding held up in external validation across thousands of additional patients. It turns out this enzyme is a marker of oxidative stress, which does have a meaningful impact on plaque build-up and heart function.

These are not exotic tests. They are measurements taken routinely in almost every patient undergoing cardiac assessment. What AI revealed is that information we were already collecting was telling us more than our existing models were capturing.

What This Means for You

Not one answer for everyone. A different answer for each person.

When the machine learning model was applied to individual patients in the SYNTAX dataset, it identified three distinct groups. For some patients, stenting and bypass surgery were predicted to produce essentially the same outcome, genuine clinical equipoise, where patient preference should play a larger role in the decision. For others, it predicted a clear advantage for bypass surgery. And for a smaller group, stenting was the stronger option.

The goal is not to have an algorithm make the decision. It is to give your heart team better information so that when they sit down with you to discuss your options, the recommendation they make is as precisely tailored to your specific situation as possible.

The quieter wins: less paperwork, more conversation

One of the less dramatic but genuinely meaningful applications of AI in medicine is the reduction of administrative burden. Cardiologists, like all doctors, spend a significant portion of their working day on documentation, dictating notes, completing forms, and reviewing records. AI-assisted tools can take notes during consultations, generate clinical summaries, and help organise information so that less time is spent on administration and more time is available for the patient in the room.

There is also a more personal dimension that is rarely discussed: what AI means for the conversation between you and your doctor. When a cardiologist tells you that an AI algorithm has analysed your scan, or that a machine learning model has helped inform the recommendation for stenting over surgery, you deserve to understand what that means and who is ultimately responsible for the decision.

The answer to that last question has not changed. Your cardiologist is responsible. AI informs; it does not decide. The shared decision between you and your clinical team remains at the centre of your care, and no algorithm changes that.

AI and Your Heart Team

One of the most important things to understand about AI in cardiology is that it does not work in isolation, and it was never designed to. The Heart Team model, where your cardiologist and cardiac surgeon review your case together before making a recommendation, is precisely where AI adds the most value. The scoring tools, the imaging analysis, the risk predictions, all of this information is brought to that meeting, discussed, and weighed alongside things that no algorithm can measure: your preferences, your circumstances, your priorities.

Traditionally, a Heart Team meeting has centred on reviewing your angiogram images on a screen, measuring segments of arteries by eye, and debating the best approach based on accumulated experience.

AI is transforming this in a concrete and visible way. Machine learning can now process your coronary imaging data and assess your arterial anatomy with a speed and precision that was not previously possible, producing accurate measurements of vessel segments, identifying the location and extent of blockages, and predicting how different stenting or bypass strategies are likely to perform in your specific anatomy.

Extended reality takes this further still. Building on work developed at the CORRIB Research Centre at the University of Galway, coronary imaging data can now be converted into a three-dimensional hologram that the entire Heart Team can explore together before any procedure begins. Rather than looking at flat images on a screen, your cardiologist and cardiac surgeon can examine a three-dimensional model of your coronary arteries, rotate it, fly through it, and measure it in precise detail. The intervention can be planned virtually before you have entered the operating theatre or the catheterisation laboratory.

This has been demonstrated in real surgical cases, including the planning of complex multi-vessel bypass operations, where holographic measurements guided decisions about which vessels to bypass and which grafts to use.

The conversation that follows is still deeply human. The decision that emerges from it is still yours to make, with your team, together. What AI and extended reality change is the quality and precision of the information on the table when that conversation happens.

What AI Cannot Do, and Why That Matters

It is just as important to be clear about the limitations of AI in cardiology as it is to acknowledge its promise. Leading clinicians in this field are the first to make this point.

AI models are trained on data from past patients. They are powerful at identifying patterns within that data, but they cannot handle what they have never seen, and they require retraining as medical knowledge evolves. A model trained predominantly on data from one type of patient population may perform less well when applied to a different population. This is why external validation across diverse groups is essential before any AI tool is used in clinical practice.

There are also important questions about data privacy, about the transparency of AI decision-making, and about ensuring that the benefits of these tools are available equitably, not just to patients in well-resourced healthcare systems.

One of the most honest concerns in this field is what researchers call the black box problem. Many AI models can tell you what conclusion they have reached, but cannot easily explain how they reached it. A neural network that identifies a high-risk plaque on a CT scan may do so with impressive accuracy, but it cannot always show the clinician its reasoning in the way that a human expert can. Different AI platforms applied to the same imaging data can sometimes reach different conclusions.

Understanding where AI is reliable, where it is uncertain, and where it requires human oversight is not a weakness of the technology. It is the essential work of responsible implementation.

Perhaps most importantly: AI does not know you. It does not know that you are frightened, or that you have a strong preference for a less invasive approach, or that your recovery will be shaped by circumstances that no dataset could capture. That knowledge belongs to your cardiologist, your cardiac surgeon, and your clinical team. The human relationship at the centre of medicine, the conversation, the trust, the shared decision, is not something that any algorithm replaces.

What This Means for You as a Patient

If you are a cardiac patient today, or if someone you love is, the most reassuring thing I can say is this. The cardiologists caring for you are not waiting passively for AI to arrive. They are actively using and evaluating these tools, carefully, with the same rigour they apply to any new treatment or technology.

The ECG you had may have been read with the assistance of an AI algorithm. The scan images of your heart may have been processed by software that flags findings for a radiologist or cardiologist to review. The risk assessment your team carried out before recommending treatment may have drawn on scoring tools developed using machine learning on large patient datasets. The intracoronary images taken during your procedure may have been analysed by neural networks that helped guide exactly where and how a stent was placed.

None of this happened instead of your doctor’s judgement. It happened alongside it, giving them better information, faster, so that the decision they made with you was as well-informed as possible.

That is what AI in cardiology is for. Not to alarm. Not to replace. Simply to help the people caring for your heart do their jobs a little better, and to give you, as a patient, the benefit of everything medicine has learned.

Conclusion

AI in cardiology is not a glimpse of some distant future. It is already in the room with you, in the ECG software that flagged your rhythm, in the imaging analysis that helped your team measure your arteries, in the risk scoring that informed your treatment plan. None of it has changed who is responsible for your care, and none of it has removed the human conversation at the heart of medicine.

What it has done is sharpen the information your cardiologist works with, shorten the time between question and answer, and extend the reach of expert care to places it could not previously go. The realistic futures, as I often put it, are arriving faster than anyone anticipated. The question is no longer whether AI will reshape how we care for patients with heart disease. It already has. The question is how thoughtfully, how rigorously, and how equitably we carry that forward.

References

  • Serruys PW. AI in Cardiovascular Imaging and Interventions: Boon or Bane? Presented at the EAPCI Summit, Munich, February 2026. Reported by TCTMD.
  • Ninomiya K, Serruys PW et al. Can Machine Learning Aid the Selection of Percutaneous vs Surgical Revascularization? Journal of the American College of Cardiology, 2023;82:2113 to 2124.
  • Serruys PW et al. 10 Years of SYNTAX: Closing an Era of Clinical Research After Identifying New Outcome Determinants. JACC: Asia, 2023.
  • American Heart Association Scientific Advisory on AI in Cardiovascular Medicine, 2025.

Related Reading

Aortic Stenosis: When the Heart’s Gateway Narrows

aortic stenosis

The aortic valve opens and closes 100,000 times a day. When it begins to narrow, the heart pays the price. Here is how aortic stenosis develops, how it is diagnosed, and how modern treatment, from open surgery to TAVR, restores flow.